| Two doses of pamidronate in infants with osteogenesis imperfecta. | |
| | |
MedLine Citation:
|
PMID: 18089634 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Current regimens of intravenous pamidronate for infants and children with osteogenesis imperfecta (OI) typically deliver 3-12 mg/kg/year of drug. We wished to ascertain the effect of pamidronate at 6 or 12 mg/kg/year on skeletal health in infants with OI. METHODS: We recruited 12 infants over a period of 4 years. Infants received either 6 or 12 mg/kg/year of pamidronate. Bone outcomes were assessed by skeletal surveys and DXA bone density measurements at baseline and at 12 months. RESULTS: Bone mass increased in both groups. Infants receiving 12 as opposed to 6 mg/kg/year pamidronate had increased spine bone density after adjusting for covariates at study entry (p = 0.04). Crush fractures improved or remained unchanged in all but one infant. Biochemical markers of bone turnover fell but remained within or above the normal range for age. Metaphyseal remodelling was not impaired. CONCLUSIONS: Pamidronate dose in infants may influence lumbar spine bone acquisition. Pamidronate improved vertebral size after prior crush fracturing and did not over-suppress bone turnover. |
| | |
Authors:
|
S Senthilnathan; E Walker; N J Bishop |
Related Documents
:
|
849004 - Neonatal hypocalcaemia after intrauterine exposure to anticonvulsant drugs. 16939184 - Rickets: not a disease of the past. 15626014 - Intracranial hemorrhage due to vitamin k deficiency after the newborn period. 17586304 - Effectiveness of an early supplementation scheme of high-dose vitamin a versus standard... 53564 - Infantile gastroenteritis: a clinical study of reovirus-like agent infection. 18967384 - Cathodic stripping voltammetry of 2,3-dichloroquinoxaline and 1,4-dichlorophthalazine r... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2007-12-18 |
Journal Detail:
|
Title: Archives of disease in childhood Volume: 93 ISSN: 1468-2044 ISO Abbreviation: Arch. Dis. Child. Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-04-22 Completed Date: 2008-05-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372434 Medline TA: Arch Dis Child Country: England |
Other Details:
|
Languages: eng Pagination: 398-400 Citation Subset: AIM; IM |
Affiliation:
|
University of Sheffield, Western Bank, Sheffield S10 2TH, UK. n.j.bishop@sheffield.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Density Bone Density Conservation Agents / administration & dosage* Bone Remodeling / drug effects Child, Preschool Diphosphonates / administration & dosage* Drug Administration Schedule Female Humans Infant Lumbar Vertebrae / chemistry Male Osteogenesis Imperfecta / drug therapy* Spine / chemistry Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 40391-99-9/pamidronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Regional differences in overweight: an effect of people or place?
Next Document: Children's consent and paediatric research: is it appropriate for healthy children to be the decisio...